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Welcome to the open-access journal titled Journal of
Clinical Bioinformatics (JCBi), a truly international jour-
nal devoted to clinical applications of bioinformatics,
medical informatics and the development of bioinfor-
matics tools, methodologies and approaches for clinical
research. JCBi aims to discover how biological and med-
ical informatics can be applied to the development of
personalized healthcare, medication and therapies. The
field of clinical bioinformatics includes the analysis of
human microarray and other omics data, combination
of bioinformatics and medical informatics, development
of bioinformatics methodologies for clinical research,
and human databases. JCBi also aims to establish a
scientific channel to translate bioinformatics to clinical
and medical application in order to better understand
molecular and cellular mechanisms and therapies for
human diseases.
Clinical bioinformatics is a new emerging science
combining clinical informatics, bioinformatics, medical
informatics, information technology, mathematics, and
omics science together. At the beginning of the 20
th
century, clinical physicians needed to be informed and
open to advances in omics technology despite the bar-
riers which existed for physicians applying genetic tests,
for example the low tolerance for uncertainty, negative
attitudes about their responsibility for genetic counseling
and testing, and unfamiliarity with ethical issues raised
by testing [1]. Since the middle of the 20
th century,
bioinformatics was suggested to be applied for clinical
toxicology [2] and cancer [3]. One of the early studies
on expressed sequence tags in human stem cells by
bioinformatics was performed in 1998 [4], where near
10000 sequences were analyzed. Of these, 48% showed
the identity to known genes in the GenBank database,
26.4% matched to the previously deposited in a public
domain database, 14% were previously undescribed
sequences, and the remaining 12% were mitochondrial
DNA, ribosomal RNA, or repetitive sequences. At the
beginning of the 21
st century, gene expression profiles
in 60 human cancer cell lines used in a drug discovery
screen were evaluated by cDNA microarrays and cor-
rected with drug activity patterns by combining bioin-
formatics and chemoinformatics [5]. Clinical
bioinformatics was initially proposed to provide biologi-
cal and medical information for individualized health-
care, enable researchers to search online biological
databases and use bioinformatics in medical practice,
select appropriate software to analyze the microarray
data for medical decision-making, optimize the develop-
ment of disease-specific biomarkers, and supervise drug
target identification and clinical validation [6].
Clinical bioinformatics plays an important role in a
number of clinical applications, including omics technol-
ogy, metabolic and signaling pathways, biomarker dis-
covery and development, computational biology,
genomics, proteomics, metaboliomics, pharmacomics,
transcriptomics, high-throughput image analysis, human
molecular genetics, human tissue bank, mathematical
medicine and biology, protein expression and profiling
and systems biology. Understanding the interaction
between clinical informatics and bioinformatics is the
first and critical step to discover and develop the new
diagnostics and therapies for diseases. Clinical bioinfor-
matics was suggested to be associated with the analysis
and visualization of complex medical datasets [7]. Differ-
ent from other informatics, clinical bioinformatics
should focus more on clinical informatics, including
patient complaints, history, therapies, clinical symptoms
and signs, physician’s examinations, biochemical ana-
lyses, imaging profiles, pathologies and other measure-
ments. It was emphasized that the simultaneous
evaluation of clinical and basic research could improve
medical care, care provision data, and data exploitation
methods in disease therapy and algorithms for the ana-
lysis of such heterogeneous data sets [8]. This particular
study tried to match disease complexity of patient infor-
mation, clinical data, standard laboratory evaluations,
brain imaging data and genetic data obtained from
molecular profiling experiments. It is a huge difficulty
and challenge to compel the clinical and biomedical
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Clinical bioinformatics failed to show the importance,
significance and clear relationships between clinical
observations and the underlying molecular mechanisms
due to the lack of integrated analysis and digitalized
informatics of clinical descriptions and measurements.
Thus, there is a great need for a scientific channel and
platform like Journal of Clinical Bioinformatics,t o
exchange information on the development, standardiza-
tion, application, and optimization of clinical bioinfor-
matics for informaticists, bioinformaticsts, cellular and
molecular biologists, pharmacologists, and clinicians.
Clinical bioinformatics is a new way to focus on the
combination of clinical measurements and signs with
human tissue-generated bioinformatics, understand clin-
ical symptoms and signs, disease development and pro-
gress, and therapeutic strategy, and map relationships
that integrate discrete elements that collectively direct
global function within a particular -omic category, with
clinical examinations, pathology, biochemical analysis,
imaging and therapies. The JCBi perspective allows
inspection and prediction of disease conditions, not lim-
ited to a monogenic challenge, but as a combination of
individualized molecular permutations acting in concert
to affect a phenotypic outcome. Bioinformatic integra-
tion of multidimensional data within and between mole-
cular biology and medicine thus harbors the potential to
identify unique biological signatures, providing an
enabling platform for advances in clinical and transla-
tional science. There is a great need to have a special
communication platform for both bioinformatics scien-
tists and clinicians to exchange their knowledge and
experience on the development of new biotechnologies,
gene and protein functions, cell and organ dysfunction,
and pathology, related to clinical signs, symptoms, find-
ings, measures, prognosis and therapeutic effects.
The term “Clinical bioinformatics“ is defined here as
“clinical application of bioinformatics-associated sciences
and technologies to understand molecular mechanisms
and potential therapies for human diseases”, a new and
important concept for the development of disease-speci-
fic biomarkers, mechanism-oriented understanding and
individualized medicine. There is solid evidence that the
generation and expansion of genomic, transcriptomic,
and proteomic data from human studies by high-
throughput biotechnologies have increased enormously.
In parallel, clinical measurements and examined infor-
mation are elevated by the development of advanced
clinical devices. Acquisition of high-dimensional datasets
to combine both clinical and biomedical information
and outcomes requires a communication platform as
archival systems that permit efficiency of storage and
retrieval. Multiple electronic repositories have been
initiated and maintained. The number of published
scientific papers related to “Clinical bioinformatics” sig-
nificantly increases every year. JCBi provides a forum for
exchange of ideas on potential molecular and cellular
mechanisms, biomarker identification and validation,
and drug discovery and development by the application
of clinical bioinformatics. JCBi will also aim to play an
important, critical, and recognized role in the improve-
ment of understanding molecular mechanisms of dis-
eases and development of new medicines. In addition,
the journal is directed toward those specialists who
work with disease-related bioinformatics, mathematics,
biostatistics and molecular biology, those who explore
drug discovery and development, pharmacology and tox-
icology, and pharmaceutical science, those who treat
patients in the clinic and develop individualized medi-
cine, and those who investigate molecular and cellular
mechanisms involved in the development and reversibil-
ity of epithelium-involved diseases.
There is an urgent and immediate need to create a
forum to stimulate discussion and exchange of scientific
findings and understandings of clinical bioinformatics
with a clear goal of treating diseases and improving the
quality of patients. JCBi is the only journal focusing on
the clinical application of bioinformatics and keeping
track of the wealth of new information related to this
topic. This is particularly the case when we observe the
rapid development of new biotechnologies, e.g. geno-
mics, proteomics, and celleomics, and the increasing
capacities of clinical investigations. We believe that the
JCBi will play an important, critical, and recognized role
in understanding the molecular mechanisms of the dis-
eases and developing the individual medicine and thera-
peutic strategy.
JCBi is also proud to be affiliated with the newly
established International Society of Translational Medi-
cine (ISTM) [9] and will be a prominent publication for
its Omics Science section. As a non-profit organization,
ISTM is a network of clinicians and researchers from all
science fields with an interest in translational medicine.
The partnership between JCBi and ISTM will assist with
the interdisciplinary research across bioinformatics and
translational medicine.
In conclusion, we as editors of JCBi, are delighted to
welcome you to this new and novel journal and thank
the scientists who have agreed to publish in the journal.
In setting up the journal, we owe an enormous debt of
gratitude to all professors and scientists for their
encouragement, support, comments, suggestions, and
contributions. With great support from our Associate
Editors and Editorial Board Members [10], we deeply
believe that JCBi will be well-received both by preclini-
cal, clinical and pharmaceutical scientists interested in
clinical bioinformatics and contribute to better outcome
for understanding the diseases and developing new
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group of scientists who work on clinical bioinformatics
are crucial to the success of the journal.
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